SIROLIMUS FOR RESCUE AND PRIMARY IMMUNOSUPPRESSION IN TRANSPLANTED CHILDREN RECEIVING TACROLIMUS1,2
Authors:
- Rakesh SindhiRSRakesh Sindhi
- Steven WebberSWSteven Webber
- Raman VenkataramananRVRaman Venkataramanan
- William McGheeWMWilliam McGhee
- Susan PhillipsSPSusan Phillips
- Amy SmithASAmy Smith
- Cynthia BairdCBCynthia Baird
- Katherine IurlanoKIKatherine Iurlano
- George MazariegosGMGeorge Mazariegos
- Brenda CooperstoneBCBrenda Cooperstone
- David W. HoltDHDavid W. Holt
- Adriana ZeeviAZAdriana Zeevi
- 1 September 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 72 (5) , 851-855
Abstract
The role of sirolimus (SRL) as a rescue agent (n=42) and as a component of primary immunosuppression (n=8) was evaluated in a mixed population of 50 transplanted children receiving tacrolimus (liver: 26, heart: 5, intestinal: 5, liver-intestine: 9, lung: 1, bone marrow: 1, liver-kidney: 1, multivisceral: 1). Rescue indications for tacrolimus (TAC) failure were recurrent acute rejection and acute rejection complicating withdrawal of immunosuppression in posttransplant lymphoproliferative disorder (PTLD). Rescue indications for TAC toxicity were nephrotoxicity, pancreatitis, seizures, hypertrophic cardiomyopathy, and graft-versus-host disease. Mean age at rescue was 11.5 years and mean follow-up was 204 (range 18–800) days. As primary immunosuppression, SRL+TAC prevented early acute rejection in 7/8 children. The indication for rescue resolved in 33/42 children. In children with TAC toxicity, this was associated with decrease in TAC doses by 50%, significant improvements in renal function, and continuing decline in Epstein-Barr virus (EBV) viral load in PTLD patients. Serious adverse events led to discontinuation of SRL in 9/42 rescue patients, 3 of them also experienced acute rejection. Three additional children also experienced acute rejection on SRL therapy (overall incidence 6/50, 12%). Pharmacokinetic analysis in the first week of SRL administration suggested a short half-life (11.8±5.5 hr, n=21). SRL and reduced-dose TAC may achieve adequate immunosuppression without compromising renal function or enhancing EBV viremia significantly.Keywords
This publication has 11 references indexed in Scilit:
- A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTSTransplantation, 2001
- Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre studyThe Lancet, 2000
- An immunoassay for the measurement of sirolimusClinical Therapeutics, 2000
- Sirolimus-tacrolimus combination immunosuppressionThe Lancet, 2000
- The role of viral load in the diagnosis, management, and possible prevention of Epstein-Barr virus–associated posttransplant lymphoproliferative disease following solid organ transplantationCurrent Opinion in Organ Transplantation, 1999
- Liver Transplantation Under Tacrolimus In Infants, Children, Adults, and Seniors: Long-Term Results, Survival, and Adverse Events in 1000 Consecutive PatientsTransplantation Proceedings, 1998
- EFFECT OF CYCLOSPORINE AND TACROLIMUS ON THE GROWTH OF EPSTEIN-BARR VIRUS-TRANSFORMED B-CELL LINES1,2Transplantation, 1998
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinaseNature, 1992
- The Use of Plasma Creatinine Concentration for Estimating Glomerular Filtration Rate in Infants, Children, and AdolescentsPediatric Clinics of North America, 1987